Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia

Reiko Watanabe, Mitsuru Murata, Nobuyuki Takayama, Michihide Tokuhira, Masahiro Kizaki, Shinichiro Okamoto, Yohko Kawai, Kiyoaki Watanabe, Hiroshi Murakami, Masao Kikuchi, Shin Nakamura, Yasuo Ikeda

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Hemostatic molecular markers were serially monitored in a prospective fashion during remission induction therapy with all-trans retinoic acid (ATRA) in sixteen patients with acute promyelocytic leukemia (APL). One patient with leukocytosis before treatment and three patients who later developed hyperleukocytosis also received chemotherapy with behenoyl Ara-C and daunorubicin. Plasma levels of E-fragment of fibrin and fibrinogen degradation product (FDP-E), FDP-D dimer (D-D), thrombin-antithrombin complex (TAT), and plasmin-α2 plasmin inhibitor complex (PIC) were markedly elevated in all but one patient before treatment, and these parameters decreased to normal or near normal ranges in most patients within the first 7 days of treatment. Interestingly, we have found that these parameters were again elevated during the later course of ATRA therapy (after day +7) in eleven patients for various reasons including cytotoxic chemotherapy (3 cases), fever (5 cases; 2cases with apparent infection, 3 cases without known etiology), Caesarean section (1 case), and no apparent etiology (2 cases). Three patients showed bleeding complications during re-elevation of molecular markers, but none developed thrombosis. Plasma elastase-α1 proteinase inhibitor complex (E-α1PI) was markedly elevated in all patients at diagnosis and did not decrease significantly during ATRA therapy. Plasma tissue factor antigen was mildly elevated in one out of four patients studied, and thrombomodulin was elevated in two out of ten patients tested. These results confirmed the rapid normalization of coagulopathy during the early phase of remission induction therapy with ATRA but suggest that re-elevation of molecular markers occurs frequently during the later course of ATRA therapy.

Original languageEnglish
Pages (from-to)641-645
Number of pages5
JournalThrombosis and Haemostasis
Volume77
Issue number4
Publication statusPublished - 1997 Apr

Fingerprint

Remission Induction
Acute Promyelocytic Leukemia
Hemostatics
Tretinoin
Therapeutics
enocitabine
Fibrin Fibrinogen Degradation Products
Thrombomodulin
Drug Therapy
Daunorubicin
Pancreatic Elastase
Leukocytosis
Thromboplastin
Cesarean Section
Reference Values
Thrombosis
Peptide Hydrolases
Fever
Hemorrhage
Antigens

ASJC Scopus subject areas

  • Hematology

Cite this

Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. / Watanabe, Reiko; Murata, Mitsuru; Takayama, Nobuyuki; Tokuhira, Michihide; Kizaki, Masahiro; Okamoto, Shinichiro; Kawai, Yohko; Watanabe, Kiyoaki; Murakami, Hiroshi; Kikuchi, Masao; Nakamura, Shin; Ikeda, Yasuo.

In: Thrombosis and Haemostasis, Vol. 77, No. 4, 04.1997, p. 641-645.

Research output: Contribution to journalArticle

Watanabe, R, Murata, M, Takayama, N, Tokuhira, M, Kizaki, M, Okamoto, S, Kawai, Y, Watanabe, K, Murakami, H, Kikuchi, M, Nakamura, S & Ikeda, Y 1997, 'Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia', Thrombosis and Haemostasis, vol. 77, no. 4, pp. 641-645.
Watanabe, Reiko ; Murata, Mitsuru ; Takayama, Nobuyuki ; Tokuhira, Michihide ; Kizaki, Masahiro ; Okamoto, Shinichiro ; Kawai, Yohko ; Watanabe, Kiyoaki ; Murakami, Hiroshi ; Kikuchi, Masao ; Nakamura, Shin ; Ikeda, Yasuo. / Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. In: Thrombosis and Haemostasis. 1997 ; Vol. 77, No. 4. pp. 641-645.
@article{18bc5e13acc649c98849e6e4bacb3225,
title = "Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia",
abstract = "Hemostatic molecular markers were serially monitored in a prospective fashion during remission induction therapy with all-trans retinoic acid (ATRA) in sixteen patients with acute promyelocytic leukemia (APL). One patient with leukocytosis before treatment and three patients who later developed hyperleukocytosis also received chemotherapy with behenoyl Ara-C and daunorubicin. Plasma levels of E-fragment of fibrin and fibrinogen degradation product (FDP-E), FDP-D dimer (D-D), thrombin-antithrombin complex (TAT), and plasmin-α2 plasmin inhibitor complex (PIC) were markedly elevated in all but one patient before treatment, and these parameters decreased to normal or near normal ranges in most patients within the first 7 days of treatment. Interestingly, we have found that these parameters were again elevated during the later course of ATRA therapy (after day +7) in eleven patients for various reasons including cytotoxic chemotherapy (3 cases), fever (5 cases; 2cases with apparent infection, 3 cases without known etiology), Caesarean section (1 case), and no apparent etiology (2 cases). Three patients showed bleeding complications during re-elevation of molecular markers, but none developed thrombosis. Plasma elastase-α1 proteinase inhibitor complex (E-α1PI) was markedly elevated in all patients at diagnosis and did not decrease significantly during ATRA therapy. Plasma tissue factor antigen was mildly elevated in one out of four patients studied, and thrombomodulin was elevated in two out of ten patients tested. These results confirmed the rapid normalization of coagulopathy during the early phase of remission induction therapy with ATRA but suggest that re-elevation of molecular markers occurs frequently during the later course of ATRA therapy.",
author = "Reiko Watanabe and Mitsuru Murata and Nobuyuki Takayama and Michihide Tokuhira and Masahiro Kizaki and Shinichiro Okamoto and Yohko Kawai and Kiyoaki Watanabe and Hiroshi Murakami and Masao Kikuchi and Shin Nakamura and Yasuo Ikeda",
year = "1997",
month = "4",
language = "English",
volume = "77",
pages = "641--645",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "4",

}

TY - JOUR

T1 - Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia

AU - Watanabe, Reiko

AU - Murata, Mitsuru

AU - Takayama, Nobuyuki

AU - Tokuhira, Michihide

AU - Kizaki, Masahiro

AU - Okamoto, Shinichiro

AU - Kawai, Yohko

AU - Watanabe, Kiyoaki

AU - Murakami, Hiroshi

AU - Kikuchi, Masao

AU - Nakamura, Shin

AU - Ikeda, Yasuo

PY - 1997/4

Y1 - 1997/4

N2 - Hemostatic molecular markers were serially monitored in a prospective fashion during remission induction therapy with all-trans retinoic acid (ATRA) in sixteen patients with acute promyelocytic leukemia (APL). One patient with leukocytosis before treatment and three patients who later developed hyperleukocytosis also received chemotherapy with behenoyl Ara-C and daunorubicin. Plasma levels of E-fragment of fibrin and fibrinogen degradation product (FDP-E), FDP-D dimer (D-D), thrombin-antithrombin complex (TAT), and plasmin-α2 plasmin inhibitor complex (PIC) were markedly elevated in all but one patient before treatment, and these parameters decreased to normal or near normal ranges in most patients within the first 7 days of treatment. Interestingly, we have found that these parameters were again elevated during the later course of ATRA therapy (after day +7) in eleven patients for various reasons including cytotoxic chemotherapy (3 cases), fever (5 cases; 2cases with apparent infection, 3 cases without known etiology), Caesarean section (1 case), and no apparent etiology (2 cases). Three patients showed bleeding complications during re-elevation of molecular markers, but none developed thrombosis. Plasma elastase-α1 proteinase inhibitor complex (E-α1PI) was markedly elevated in all patients at diagnosis and did not decrease significantly during ATRA therapy. Plasma tissue factor antigen was mildly elevated in one out of four patients studied, and thrombomodulin was elevated in two out of ten patients tested. These results confirmed the rapid normalization of coagulopathy during the early phase of remission induction therapy with ATRA but suggest that re-elevation of molecular markers occurs frequently during the later course of ATRA therapy.

AB - Hemostatic molecular markers were serially monitored in a prospective fashion during remission induction therapy with all-trans retinoic acid (ATRA) in sixteen patients with acute promyelocytic leukemia (APL). One patient with leukocytosis before treatment and three patients who later developed hyperleukocytosis also received chemotherapy with behenoyl Ara-C and daunorubicin. Plasma levels of E-fragment of fibrin and fibrinogen degradation product (FDP-E), FDP-D dimer (D-D), thrombin-antithrombin complex (TAT), and plasmin-α2 plasmin inhibitor complex (PIC) were markedly elevated in all but one patient before treatment, and these parameters decreased to normal or near normal ranges in most patients within the first 7 days of treatment. Interestingly, we have found that these parameters were again elevated during the later course of ATRA therapy (after day +7) in eleven patients for various reasons including cytotoxic chemotherapy (3 cases), fever (5 cases; 2cases with apparent infection, 3 cases without known etiology), Caesarean section (1 case), and no apparent etiology (2 cases). Three patients showed bleeding complications during re-elevation of molecular markers, but none developed thrombosis. Plasma elastase-α1 proteinase inhibitor complex (E-α1PI) was markedly elevated in all patients at diagnosis and did not decrease significantly during ATRA therapy. Plasma tissue factor antigen was mildly elevated in one out of four patients studied, and thrombomodulin was elevated in two out of ten patients tested. These results confirmed the rapid normalization of coagulopathy during the early phase of remission induction therapy with ATRA but suggest that re-elevation of molecular markers occurs frequently during the later course of ATRA therapy.

UR - http://www.scopus.com/inward/record.url?scp=0030939471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030939471&partnerID=8YFLogxK

M3 - Article

VL - 77

SP - 641

EP - 645

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 4

ER -